NYSE:NGVT

Ingevity Stock Forecast, Price & News

$81.11
-2.50 (-2.99 %)
(As of 06/14/2021 01:23 PM ET)
Add
Compare
Today's Range
$81.06
$82.98
50-Day Range
$70.45
$89.41
52-Week Range
$46.50
$89.55
Volume2,104 shs
Average Volume252,016 shs
Market Capitalization$3.25 billion
P/E Ratio17.59
Dividend YieldN/A
Beta2.2
30 days | 90 days | 365 days | Advanced Chart
Receive NGVT News and Ratings via Email

Sign-up to receive the latest news and ratings for Ingevity and its competitors with MarketBeat's FREE daily newsletter.


Ingevity logo

About Ingevity

Ingevity Corporation manufactures and sells specialty chemicals and activated carbon materials in North America, the Asia-Pacific, Europe, the Middle East, Africa, and South America. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products primarily for use in gasoline vapor emission control systems in cars, motorcycles, trucks, and boats. This segment also produces other activated carbon products for use in various applications, including food, water, beverage, and chemical purification. The Performance Chemicals segment develops, manufactures, and sells a range of specialty chemicals derived from co-products of the kraft pulping process and caprolactone monomers. This segment's products are used in various applications comprising warm mix paving, pavement preservation, pavement reconstruction and recycling, oil well service additives, oil production, and downstream applications; and adhesives, agrochemical dispersants, lubricants, printing inks, coatings, resins, elastomers, bioplastics, medical devices, and other industrial applications. Ingevity Corporation was incorporated in 2015 and is headquartered in North Charleston, South Carolina.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.61 out of 5 stars

Basic Materials Sector

150th out of 894 stocks

Chemicals & Allied Products Industry

11th out of 30 stocks

Analyst Opinion: 1.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ingevity (NYSE:NGVT) Frequently Asked Questions

Is Ingevity a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ingevity stock.
View analyst ratings for Ingevity
or view top-rated stocks.

What stocks does MarketBeat like better than Ingevity?

Wall Street analysts have given Ingevity a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ingevity wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ingevity's next earnings date?

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Ingevity
.

How were Ingevity's earnings last quarter?

Ingevity Co. (NYSE:NGVT) issued its quarterly earnings data on Wednesday, April, 28th. The company reported $1.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.03 by $0.24. The firm earned $320.30 million during the quarter, compared to analysts' expectations of $293.05 million. Ingevity had a net margin of 15.19% and a trailing twelve-month return on equity of 33.94%. The firm's quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the company earned $1.12 earnings per share.
View Ingevity's earnings history
.

How has Ingevity's stock price been impacted by Coronavirus?

Ingevity's stock was trading at $38.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NGVT stock has increased by 109.9% and is now trading at $81.43.
View which stocks have been most impacted by COVID-19
.

What guidance has Ingevity issued on next quarter's earnings?

Ingevity updated its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $1.28 billion-$1.33 billion, compared to the consensus revenue estimate of $1.29 billion.

What price target have analysts set for NGVT?

5 brokerages have issued 1 year price objectives for Ingevity's shares. Their forecasts range from $58.00 to $110.00. On average, they anticipate Ingevity's share price to reach $80.80 in the next twelve months. This suggests that the stock has a possible downside of 0.8%.
View analysts' price targets for Ingevity
or view top-rated stocks among Wall Street analysts.

Who are Ingevity's key executives?

Ingevity's management team includes the following people:
  • Mr. John C. Fortson, Pres, CEO, Interim Treasurer & Director (Age 54, Pay $1.2M)
  • Mr. Stuart Edward Woodcock Jr., Exec. VP & Pres of Performance Materials (Age 55, Pay $822.04k)
  • Mr. Michael P. Smith, Exec. VP and Pres of Performance Chemicals, Strategy & Bus. Devel. (Age 60, Pay $736.31k)
  • Ms. Mary Dean Hall, Exec. VP & CFO (Age 63)
  • Mr. Phillip John Platt, Chief Accounting Officer & Corp. Controller (Age 40)
  • Mr. Daniel Gallagher, VP of Investor Relations
  • Mr. Bill Hamilton, Treasurer & VP of Investor Relations
  • Ms. Stacy Lancaster Cozad, Exec. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Jack Maurer, Sr. VP of Public Affairs
  • Ms. Cynthia Cartmell Burns, Sr. VP of HR

What is John Fortson's approval rating as Ingevity's CEO?

2 employees have rated Ingevity CEO John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among Ingevity's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Ingevity's key competitors?

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), The Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

What is Ingevity's stock symbol?

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Who are Ingevity's major shareholders?

Ingevity's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.87%), Boston Partners (5.72%), LSV Asset Management (2.60%), Ardevora Asset Management LLP (1.83%), Dimensional Fund Advisors LP (1.77%) and Lazard Asset Management LLC (1.76%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, Richard B Kelson and Stuart Edward Jr Woodcock.
View institutional ownership trends for Ingevity
.

Which institutional investors are selling Ingevity stock?

NGVT stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Arrowstreet Capital Limited Partnership, UBS Asset Management Americas Inc., Loomis Sayles & Co. L P, Price T Rowe Associates Inc. MD, Lazard Asset Management LLC, LSV Asset Management, and Maple Rock Capital Partners Inc..
View insider buying and selling activity for Ingevity
or view top insider-selling stocks.

Which institutional investors are buying Ingevity stock?

NGVT stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Glenmede Trust Co. NA, Inclusive Capital Partners L.P., Boston Partners, Schroder Investment Management Group, D. E. Shaw & Co. Inc., Voloridge Investment Management LLC, and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson.
View insider buying and selling activity for Ingevity
or or view top insider-buying stocks.

How do I buy shares of Ingevity?

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ingevity's stock price today?

One share of NGVT stock can currently be purchased for approximately $81.43.

How much money does Ingevity make?

Ingevity has a market capitalization of $3.26 billion and generates $1.22 billion in revenue each year. The company earns $181.40 million in net income (profit) each year or $4.88 on an earnings per share basis.

How many employees does Ingevity have?

Ingevity employs 1,750 workers across the globe.

What is Ingevity's official website?

The official website for Ingevity is www.ingevity.com.

Where are Ingevity's headquarters?

Ingevity is headquartered at 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406.

How can I contact Ingevity?

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The company can be reached via phone at (844) 643-8489 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.